Chargement...

Robocath secures €40 million series C financing round to deploy its operations development plan

29 April 2020

Rouen, France, April 29, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has secured €40 million ($43M) in a series C round of financing. This was led by MicroPort Scientific Corporation (HKG:853), a major listed industrial player in the cardiovascular field, with participation from institutional investors (Zhejiang Silk Road Fund, Luxembourg CLIIF managed under TUS-Holdings, CS Group and Anaxago) as well as existing Robocath investors (1).

Learn more

Robocath successfully completes first robotic coronary angioplasties in Germany with R-One™

21 January 2020

Rouen, France, January 21, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has successfully completed its first robotic coronary angioplasties with R-One™ in Germany. The Percutaneous Coronary Interventions (PCI) were performed by Prof. Michael Haude, a recognized and highly experienced interventional cardiologist at Rheinland Klinikum Neuss Lukaskrankenhaus, and his team.  

Prof. Michael Haude, Director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, said, “I’m proud…

Learn more
Subscribe to our newsletter
29 January 2020

High Tech Cardio 2020 - Marseille (France)